According to recent regulatory filings with the SEC, Roy D. Baynes, a director at Travere Therapeutics, Inc. (NASDAQ:TVTX), has executed a series of transactions involving the company's common stock. On May 1, 2026, Mr. Baynes sold 9,750 shares of common stock at a price of $44.22 per share, resulting in total proceeds of $431,145.
The sale was not an impromptu market move but was performed pursuant to a pre-arranged Rule 10b5-1(c) trading plan. This specific plan had been adopted by the director on November 17, 2025. The shares involved in this disposal were originally acquired through the exercise of stock options granted to Mr. Baynes.
In tandem with the sale, Mr. Baynes also engaged in an acquisition of shares via the exercise of stock options on the same day. He exercised options for 9,750 shares of Travere Therapeutics common stock at a price of $6.82 per share, representing a total value of $66,495. These options were noted as being fully vested and exercisable at the time of the transaction. Following these combined actions, Mr. Baynes holds a direct position of 37,500 shares of common stock and maintains 9,750 derivative shares in the form of stock options.
The timing of this insider activity coincides with a period of notable volatility and growth for TVTX. The stock is currently trading at $44.92, which is positioned near its 52-week high of $44.70. Over the course of the previous year, Travere's shares have experienced a surge of more than 108%, bringing the company's total market capitalization to $4.14 billion. Despite this upward momentum, analysis from InvestingPro suggests that the stock may still be trading below its calculated Fair Value.
This insider transaction follows a period of mixed financial performance for Travere Therapeutics. The company's first-quarter results recently fell short of expectations from Wall Street analysts. While revenue grew to $127.2 million - a significant increase from the $77.4 million reported in the same quarter of the previous year - it did not reach the anticipated $137.34 million. Additionally, the reported loss of $0.40 per share was wider than the consensus estimate of a $0.23 loss.
On a more positive note, U.S. net product sales saw an increase to $124.5 million, compared to $75.9 million in the first quarter of last year. A primary driver was the performance of FILSPARI in IgAN, which saw year-over-year growth of 88%, totaling $105.2 million. This growth was supported by a record 993 new patient start forms received during the quarter. However, despite this high demand for FILSPARI, these figures were not enough to prevent the company from missing its overall revenue and earnings expectations.